LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway

Biochemical and Biophysical Research Communications

Volumn 377, Issue 1, 2008, Pages 187-190

  Liu, Peng ^a   Xu, Bei ^a   Li, Jianyong ^a   Lu, Hua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Egr 1; Invasion; Leukemia; LY294002; PI3K

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EARLY GROWTH RESPONSE FACTOR 1; LY 303511; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN INDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL MOVEMENT; CHROMONES; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MORPHOLINES; NEOPLASM INVASIVENESS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 54449097733     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.09.094     Document Type: Article

References (23)

1. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
2. Yamaguchi K., Lee S.H., Kim J.S., Wimalasena J., Kitajima S., and Baek S.J. Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. Cancer Res. 66 (2006) 2376-2384
3. Ramos A.M., Fernandez C., Amran D., Sancho P., de Blas E., and Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105 (2005) 4013-4020
4. Tabellini G., Cappellini A., Tazzari P.L., Fala F., Billi A.M., Manzoli L., Cocco L., and Martelli A.M. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J. Cell. Physiol. 202 (2005) 623-634
5. Tokunaga E., Oki E., Egashira A., Sadanaga N., Morita M., Kakeji Y., and Maehara Y. Deregulation of the Akt pathway in human cancer. Curr. Cancer Drug Targets 8 (2008) 27-36
6. Cheng G.Z., Park S., Shu S., He L., Kong W., Zhang W., Yuan Z., Wang L.H., and Cheng J.Q. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 8 (2008) 2-6
7. Poh T.W., and Pervaiz S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res. 65 (2005) 6264-6274
8. Whitley B.R., Beaulieu L.M., Carter J.C., and Church F.C. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol. Oncol. 104 (2007) 470-479
9. Shukla S., Maclennan G.T., Hartman D.J., Fu P., Resnick M.I., and Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Cancer 121 (2007) 1424-1432
10. Yoon S.O., Shin S., Lee H.J., Chun H.K., and Chung A.S. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol. Cancer Ther. 5 (2006) 2666-2675
11. Baek S.J., Kim J.S., Moore S.M., Lee S.H., Martinez J., and Eling T.E. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol. Pharmacol. 67 (2005) 356-364
12. Liu C., Yao J., Mercola D., and Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J. Biol. Chem. 275 (2000) 20315-20323
13. Shingu T., and Bornstein P. Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene. J. Biol. Chem. 269 (1994) 32551-32557
14. Redondo-Munoz J., Escobar-Diaz E., Samaniego R., Terol M.J., Garcia-Marco J.A., and Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108 (2006) 3143-3151
15. Kelly B.D., Hackett S.F., Hirota K., Oshima Y., Cai Z., Berg-Dixon S., Rowan A., Yan Z., Campochiaro P.A., and Semenza G.L. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93 (2003) 1074-1081
16. Kim S.O., Kwon J.I., Jeong Y.K., Kim G.Y., Kim N.D., and Choi Y.H. Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells. Biosci. Biotechnol. Biochem. 71 (2007) 2169-2176
17. Moon Y., Bottone Jr. F.G., McEntee M.F., and Eling T.E. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Mol. Cancer Ther. 4 (2005) 1551-1558
18. Lucerna M., Pomyje J., Mechtcheriakova D., Kadl A., Gruber F., Bilban M., Sobanov Y., Schabbauer G., Breuss J., Wagner O., Bischoff M., Clauss M., Binder B.R., and Hofer E. Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res. 66 (2006) 6708-6713
19. Gibbs J.D., Liebermann D.A., and Hoffman B. Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia. Oncogene 27 (2008) 98-106
20. Gibbs J.D., Liebermann D.A., and Hoffman B. Leukemia suppressor function of Egr-1 is dependent on transforming oncogene. Leukemia (2008) [Epub ahead of print]
21. Shafarenko M., Liebermann D.A., and Hoffman B. Egr-1 abrogates the block imparted by c-Myc on terminal M1 myeloid differentiation. Blood 106 (2005) 871-878
22. Choi E.K., Park H.J., Ma J.S., Lee H.C., Kang H.C., Kim B.G., and Kang I.C. LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism. FEBS Lett. 559 (2004) 141-144
23. Rahmani M., Yu C., Reese E., Ahmed W., Hirsch K., Dent P., and Grant S. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene 22 (2003) 6231-6242